View More Recent Stories
-
InMed Pharmaceuticals Inc. (INM) Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease
-
InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease
-
InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease
-
InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board
-
InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update
-
InMed (INM) Receives NASDAQ Delisting Notice
-
InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date
-
InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents
-
InMed Pharmaceuticals (INM) Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease
-
InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease
-
InMed Pharmaceuticals Inc. (INM) Receives Favorable Behavioral Outcomes with INM-901
-
InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data
-
InMed to Present at the Emerging Growth Conference
